247 related articles for article (PubMed ID: 17495026)
21. Potential role of CYLD (Cylindromatosis) as a deubiquitinating enzyme in vascular cells.
Takami Y; Nakagami H; Morishita R; Katsuya T; Hayashi H; Mori M; Koriyama H; Baba Y; Yasuda O; Rakugi H; Ogihara T; Kaneda Y
Am J Pathol; 2008 Mar; 172(3):818-29. PubMed ID: 18245814
[TBL] [Abstract][Full Text] [Related]
22. The tumor suppressor cylindromatosis (CYLD) acts as a negative regulator for toll-like receptor 2 signaling via negative cross-talk with TRAF6 AND TRAF7.
Yoshida H; Jono H; Kai H; Li JD
J Biol Chem; 2005 Dec; 280(49):41111-21. PubMed ID: 16230348
[TBL] [Abstract][Full Text] [Related]
23. CYLD-mediated signaling and diseases.
Mathis BJ; Lai Y; Qu C; Janicki JS; Cui T
Curr Drug Targets; 2015; 16(4):284-94. PubMed ID: 25342597
[TBL] [Abstract][Full Text] [Related]
24. Regulation of the deubiquitinating enzyme CYLD by IkappaB kinase gamma-dependent phosphorylation.
Reiley W; Zhang M; Wu X; Granger E; Sun SC
Mol Cell Biol; 2005 May; 25(10):3886-95. PubMed ID: 15870263
[TBL] [Abstract][Full Text] [Related]
25. The tumor suppressor CYLD interacts with TRIP and regulates negatively nuclear factor kappaB activation by tumor necrosis factor.
Regamey A; Hohl D; Liu JW; Roger T; Kogerman P; Toftgard R; Huber M
J Exp Med; 2003 Dec; 198(12):1959-64. PubMed ID: 14676304
[TBL] [Abstract][Full Text] [Related]
26. SPATA2 Links CYLD to LUBAC, Activates CYLD, and Controls LUBAC Signaling.
Elliott PR; Leske D; Hrdinka M; Bagola K; Fiil BK; McLaughlin SH; Wagstaff J; Volkmar N; Christianson JC; Kessler BM; Freund SM; Komander D; Gyrd-Hansen M
Mol Cell; 2016 Sep; 63(6):990-1005. PubMed ID: 27591049
[TBL] [Abstract][Full Text] [Related]
27. The tumor suppressor CYLD controls the function of murine regulatory T cells.
Reissig S; Hövelmeyer N; Weigmann B; Nikolaev A; Kalt B; Wunderlich TF; Hahn M; Neurath MF; Waisman A
J Immunol; 2012 Nov; 189(10):4770-6. PubMed ID: 23066153
[TBL] [Abstract][Full Text] [Related]
28. Cylindromatosis and the CYLD gene: new lessons on the molecular principles of epithelial growth control.
Massoumi R; Paus R
Bioessays; 2007 Dec; 29(12):1203-14. PubMed ID: 18008375
[TBL] [Abstract][Full Text] [Related]
29. Suppression of LUBAC-mediated linear ubiquitination by a specific interaction between LUBAC and the deubiquitinases CYLD and OTULIN.
Takiuchi T; Nakagawa T; Tamiya H; Fujita H; Sasaki Y; Saeki Y; Takeda H; Sawasaki T; Buchberger A; Kimura T; Iwai K
Genes Cells; 2014 Mar; 19(3):254-72. PubMed ID: 24461064
[TBL] [Abstract][Full Text] [Related]
30. CYLD: a multifunctional deubiquitinase.
Glittenberg M; Ligoxygakis P
Fly (Austin); 2007; 1(6):330-2. PubMed ID: 18820455
[TBL] [Abstract][Full Text] [Related]
31. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling.
Massoumi R; Chmielarska K; Hennecke K; Pfeifer A; Fässler R
Cell; 2006 May; 125(4):665-77. PubMed ID: 16713561
[TBL] [Abstract][Full Text] [Related]
32. CYLD in ubiquitin signaling and tumor pathogenesis.
Ikeda F; Dikic I
Cell; 2006 May; 125(4):643-5. PubMed ID: 16713556
[TBL] [Abstract][Full Text] [Related]
33. The K48-K63 Branched Ubiquitin Chain Regulates NF-κB Signaling.
Ohtake F; Saeki Y; Ishido S; Kanno J; Tanaka K
Mol Cell; 2016 Oct; 64(2):251-266. PubMed ID: 27746020
[TBL] [Abstract][Full Text] [Related]
34. Five new CYLD mutations in skin appendage tumors and evidence that aspartic acid 681 in CYLD is essential for deubiquitinase activity.
Almeida S; Maillard C; Itin P; Hohl D; Huber M
J Invest Dermatol; 2008 Mar; 128(3):587-93. PubMed ID: 17851586
[TBL] [Abstract][Full Text] [Related]
35. CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin.
Wickström SA; Masoumi KC; Khochbin S; Fässler R; Massoumi R
EMBO J; 2010 Jan; 29(1):131-44. PubMed ID: 19893491
[TBL] [Abstract][Full Text] [Related]
36. Downregulation of LEF1 Impairs Myeloma Cell Growth Through Modulating CYLD/NF-κB Signaling.
Zhang G; Miao F; Liu K; Wu J; Xu J
Technol Cancer Res Treat; 2021; 20():15330338211034270. PubMed ID: 34269120
[TBL] [Abstract][Full Text] [Related]
37. Regulation of early wave of germ cell apoptosis and spermatogenesis by deubiquitinating enzyme CYLD.
Wright A; Reiley WW; Chang M; Jin W; Lee AJ; Zhang M; Sun SC
Dev Cell; 2007 Nov; 13(5):705-716. PubMed ID: 17981138
[TBL] [Abstract][Full Text] [Related]
38. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB.
Brummelkamp TR; Nijman SM; Dirac AM; Bernards R
Nature; 2003 Aug; 424(6950):797-801. PubMed ID: 12917690
[TBL] [Abstract][Full Text] [Related]
39. miR-20a induces cisplatin resistance of a human gastric cancer cell line via targeting CYLD.
Zhu M; Zhou X; Du Y; Huang Z; Zhu J; Xu J; Cheng G; Shu Y; Liu P; Zhu W; Wang T
Mol Med Rep; 2016 Aug; 14(2):1742-50. PubMed ID: 27357419
[TBL] [Abstract][Full Text] [Related]
40. Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation.
Hutti JE; Shen RR; Abbott DW; Zhou AY; Sprott KM; Asara JM; Hahn WC; Cantley LC
Mol Cell; 2009 May; 34(4):461-72. PubMed ID: 19481526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
